Pfizer Is Pursuing A Booster Shot And New Vaccine Targeting The Delta Variant Federal health officials say a booster isn't currently needed for anyone fully vaccinated against COVID-19.

The White House has started the process of rolling out a plan for boosters. Read on for what we know about COVID-19 booster shots today, including who can get the Pfizer boosters with the CDC's ...

The U.S. Food and Drug Administration authorized a booster shot of the two-dose Pfizer-BioNTech COVID-19 vaccine late Sept. 22 after an internal advisory committee voted in support of them the ...

Pfizer and BioNTech say a booster shot for their COVID-19 vaccine extends protection against the coronavirus. The companies have not submitted the booster for FDA approval yet.

Pfizer asked the FDA to approve booster doses of its vaccine in late August by submitting an application and data, which started the process. On Wednesday morning, the FDA made that data public.

Pfizer is promoting a third-dose booster shot of its COVID-19 vaccine but has not delivered conclusive proof to back up its effectiveness.

Pfizer and its German partner, BioNTech, announced Friday that their updated coronavirus booster shot targeting the omicron variant succeeded in strengthening the body’s army of disease-fighting ...

The U.S. Food and Drug Administration authorized a booster shot of the two-dose Pfizer-BioNTech COVID-19 vaccine late Sept. 22 after an internal advisory committee voted in support of them the ...

A Food and Drug Administration panel voted against giving most Americans a third Pfizer vaccine despite President Biden's plan to provide a COVID-19 booster to anyone over the age of 16.

Pfizer booster authorized for ages 16 and up 03:16. The Centers for Disease Control and Prevention is recommending that Americans as young as 16 get a booster shot of COVID-19 vaccine. The ...

COVID vaccine cocktails: A guide to mixing and matching Pfizer, Moderna, J&J booster shots On Oct. 21, the CDC OK'd booster doses from competing companies.

Pfizer and BioNTech believe their existing vaccine still offers good protection against circulating variants, and see the plan as a way of learning how to deal with a more threatening mutation.